Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
《基因編輯》Editas 鐮狀細胞基因編輯療法顯示出早期的希望，但能對抗 Vertex /CRISPR的exa-cel( CTX001 ...
FDA Grants Orphan Drug Statis New CTX001 Gene Therapy Trial by the ...
ASH: CRISPR, Vertex' CTX001 hits the mark in red cell disorders ...
Comparing Crispr Therapeutics' CTX001 vs. Bluebird Bio's lovo-cel ...
Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β ...
Comparing Crispr Therapeutics' CTX001 vs. Bluebird Bio's Beti-Cel ...
CTX001 Has Now Dosed Over 70 Patients. : r/CrisprTherapeutics
CTX001 FDA Approval Prediction Date. (Ep. 227) - YouTube
CTx001 for Geographic Atrophy: A Gene Therapy Expressing Soluble ...
Gene-Editing Therapy CTX001 Reports Durable Effects for TDT, Sickle ...
CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data
CTX001 Changes name, CRISPR news again. : r/CRISPR
CTX001 for Beta Thalassemia Clinical Trial 2023 | Power
Open Discussion on FDA Approval CTX001 CRISPR : r/CRISPR
EFFICACY AND SAFETY OF A SINGLE DOSE OF CTX001 FOR.... EHA Library ...
Complement Therapeutics starts Opti-GAIN trial for CTx001 in Geographic ...
First Patient Receives CTx001 in Opti-GAIN Study for AMD ...
Banker predicts Exa-Cel CTX001 to be FDA Approved - YouTube
News: CRISPR Therapy Turns a Corner With First Cures In Sight - CRISPR ...
首款获批上市CRISPR基因编辑药物设计思路和难关攻克。 - 知乎
CRISPR基因编辑技术治疗TDT和SCD的最新数据公布
Pedro Morais on LinkedIn: #casgevy #ctx001 #cd34 #hspcs #crispr #cas9 # ...
CRISPR Gene Therapy: A Promising One-Time Therapeutic Approach for ...
World's First Approval of CRISPR-Based Gene-Editing Treatment: CASGEVY ...
CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA ...
美股市值最高的基因编辑公司—CRISPR Therapeutics - 知乎
Slide 8
CRISPR Therapeutics and Vertex Announce New Clinical Data
基因编辑人体试验解禁！美国首例CRISPR疗法获批临床_CTX001
RNA疗法的研究进展：从实验室到临床-MedSci.cn
Slide 19
Vertex/CRISPR基因编辑疗法CTX001最新临床数据将在EHA年会上公布 编译丨范东东日前，Vertex和CRISPR公布了 ...
crsp-10k_20191231.htm
全球首款CRISPR基因疗法（CRISPR Therapeutics公司）即将获批 CRISPR Therapeutics 可能即将实现基因 ...
نخستین داروی ویرایش ژنوم برای درمان بیماران مبتلا به تالاسمی به زودی ...
Great follow up results on two treated patients for sickle cell and ...
上市公司首次公布基於CRISPR開發的同種異體CAR-T臨床前研究結果 - 每日頭條
NEJM医学前沿
镰状细胞病(SCD)新药！CRISPR/Cas9基因编辑疗法CTX001：1次输注，快速持久提高血红蛋白水平! - 投资专区 - 生物谷
Slide 18
CRISPR疗法 顶点报告了基因编辑治疗CTX001试验的第一批数据 - 中国基因网
首个CRISPR基因编辑疗法！美国FDA授予exa-cel(CTX001)滚动审查! - 投资专区 - 生物谷
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia | NEJM
CTX001: CRISPR Therapeutics and Vertex Present Positive Clinical Data ...
Precise Gene Editing's Impact on Sickle Cell Disease | IDT
CRISPR Therapeutics： CTX001有望成为首个治疗TDT/SCD的CRISPR- Cas9药物医药新闻-ByDrug-一站 ...
临床中的脱靶风险评估-CRISPR安全评估系列专题（二） - 知乎
Expanding Horizons of CRISPR/Cas Technology: Clinical Advancements ...
Cutting Edge Gene Therapies: Beta-Thalassemia Breakthroughs (Part I ...
CTX110治疗复发或难治性 B 细胞 CD19+ 恶性肿瘤的临床数据及安全性_患者
CTX001: FDA-Approved CRISPR Treatment for Sickle Cell Disease and Beta ...
FDA Grants RMAT Designation to CTX-001™ for the Treatment of Severe TDT ...
Slide 17
An overview of Genome editing using CRISPR - Cas 9.pdf
Treating genetic blood disorders in the era of CRISPR-mediated genome ...
ANX005, CTx001, and the Rise of Epitope-Guided Immunotherapy
Gene-editing Therapy CTX-001 Granted Priority Medicines Designation for ...
Slide 20
CRISPR Therapeutics, Vertex Report First Data from Trials of Gene ...
Progressing toward in vivo CRISPR Gene Editing in the Clinic ...
Slide 15
Slide 12
基因魔剪！CRISPR/Cas9基因编辑造血干细胞疗法CTX001获欧盟优先药物资格(PRIME)：治疗2种血红蛋白病! - 干细胞&iPS ...
CRISPR and Vertex Pharmaceuticals Win RMAT for CTX001™
Vertex 和 CRISPR Therapeutics 的 CASGEVY 获得 FDA 批准--这是世界上首个使用 CRISPR 基因编辑 ...
Gene Editing_ Rewriting the Code of Life.pptx
基因魔剪！CRISPR/Cas9基因编辑造血干细胞疗法CTX001获美国FDA授予快速通道资格，治疗2种血红蛋白病 - 投资专区 - 生物谷
Slide 16
体外编辑上市一步之遥，CRISPR基因体内编辑疗法进展|CRISPR|基因|数据|临床|-健康界
Cortalix Nanobody Pipeline – From Discovery to Preclinical Product
The FDA Has Just Put The Brakes on a Major CRISPR Trial in Humans ...
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With ...
Vertex全球首款治疗SCD（镰刀细胞贫血）的CRISPR基因编辑药物即将获批，而这只是第一步 - 知乎
CRISPR-Cas System: The Current and Emerging Translational Landscape
CRISPR/Cas9基因编辑疗法获FDA批准治疗β地中海贫血医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
BCL11A enhancer dissection by Cas9-mediated in situ saturating ...
CLIMB THAL111SCD121 Phase III Studies of CTX 001
Slide 13
CRISPR to fix bad blood: a new tool in basic and clinical hematology ...
Solved DISCUSSION We report the investigational use of | Chegg.com
#crispr #geneediting #biotechinnovation #scientificresearch | Yash Dadhich
重磅！首款CRISPR基因编辑疗法获FDA批准上市|基因编辑|FDA_新浪新闻
基因编辑疗法 | 从“常常帮助”到“偶尔治愈” - 知乎
ASH｜功能性治愈潜力显现，CTX001基因疗法能否在未来大放异彩？ - 药时代DrugTimes
CTX001試驗結果積極，CRISPR Therapeutics是目前最佳的基因編輯概念股嗎？ | NAI 500
크리스퍼-버텍스 "CRISPR 상업화 임상 유럽서 최초개시" - 바이오스펙테이터
CRISPR-Cas问题集|CRISPR-Cas9实验中常见问题及解决方案 - 知乎
CTx-001 - Drug Targets, Indications, Patents - Synapse
CRISPR-CAS9 modified CD34+ human hematopoietic stem and progenitor ...
CRISPR Therapeutics and Vertex Announce FDA Has Lifted the Clinical ...
CRISPR药物Casgevy开启基因编辑时代【热点观察】医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
2023年11项值得关注的临床试验医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
First CRISPR gene therapy approved!
Complement Therapeutics Secures €72M Series A Financing to Advance One ...
Current clinical trials in hematology using the CRISPR/Cas9 system ...
β-地贫基因疗法全球格局一览：慢病毒整合与CRISPR编辑到底谁更具优势？ 2022年11月23日/医麦客新闻 eMedClub News ...
[レビュー] 標的遺伝子挿入：血友病治療法から切り開かれたCRISPR医薬の最先端 : crisp_bio
中国基因编辑CAR-T首登Nature！详解下一代细胞疗法的|Nature|CRISPR|基因组|生物学|疗法|基因|细胞|-健康界
CRISPR Gene Editing Delivers Promise for Sickle-Cell Disease, Beta ...
Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and ...
CETERIX ORTHOPAEDICS: CTX-C001
_highres.jpg?download=1){kind=logo}
